Interactions of MRZ 2/576 with felbamate, lamotrigine, oxcarbazepine and topiramate in the mouse maximal electroshock-induced seizure model

Pharmacology

Volumn 81, Issue 3, 2008, Pages 259-265

  Luszczki, Jarogniew J ^a,b   Danysz, Wojciech ^c   Czuczwar, Stanislaw J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Drug interaction; Felbamate; Isobolographic analysis; Lamotrigine; Maximal electroshock seizure test; MRZ 2 576; Oxcarbazepine; Subthreshold method; Topiramate

Indexed keywords

ANTICONVULSIVE AGENT; FELBAMATE; LAMOTRIGINE; MRZ 2576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXCARBAZEPINE; TOPIRAMATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ELECTRIC SHOCK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE; STATISTICAL ANALYSIS;

ANIMALS; ANTICONVULSANTS; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROSHOCK; FRUCTOSE; INJECTIONS, INTRAPERITONEAL; MALE; MICE; PHENYLCARBAMATES; PHTHALAZINES; PROPYLENE GLYCOLS; RECEPTORS, N-METHYL-D-ASPARTATE; SEIZURES; TRIAZINES;

EID: 41349113787     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000114870     Document Type: Article

References (25)

1. Kwan P, Brodie MJ: Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
2. Kwan P, Brodie MJ: Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9:464-468.
3. Stephen LJ, Brodie MJ: Seizure freedom with more than one antiepileptic drug. Seizure 2002;11:349-351.
4. Czuczwar SJ, Patsalos PN: The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15:339-350.
5. Macdonald RL, Greenfield LJ: Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997;10:121-128.
6. Parsons CG, Danysz W, Quack G, Hartmann S, Lorenz B, Wollenburg C, Baran L, Przegalinski E, Kostowski W, Krzascik P, Chizh B, Headley PM: Novel systemically active antagonists of the glycine site of the N -methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther 1997;283:1264-1275.
7. B site receptor antagonists inhibit morphine tolerance. Neuropharmacology 2005;48:360-371.
8. Makarska-Bialek K, Kaminski RM, Czuczwar SJ: Influence of the antagonist of the glycine site of NMDA receptors, MRZ 2/576, on the anticonvulsant activity of conventional antiepileptic drugs in mice. Pharmacol Rep 2005;57:458-466.
9. Löscher W, Fassbender CP, Nolting B: The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 1991;8:79-94.
10. Luszczki JJ, Czuczwar SJ: Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis. Epilepsia 2004;45:895-907.
11. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.
12. Luszczki JJ, Czuczwar SJ: How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep 2005;57:782-786.
13. Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ: Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:489-499.
14. Luszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2006;373:169-181.
15. Berenbaum MC: What is synergy? Pharmacol Rev 1989;41:93-141. Erratum published in Pharmacol Rev 1989;41:422.
16. Tallarida RJ: Drug Synergism and Dose-Effect Data Analysis. Boca Raton, Chapman & Hall/CRC, 2000.
17. Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-290.
18. Kerry DW, Hamilton-Miller JMT, Brumfitt W: Trimethoprim and rifampicin: in vitro activities separately and in combination. J Antimicrob Chemother 1975;1:417-427.
19. Bourgeois BFD: Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther 1988;247:1128-1132.
20. Borowicz KK, Luszczki JJ, Czuczwar SJ: Isobolographic and subthreshold analysis of interactions among felbamate and four conventional antiepileptic drugs in pen tylenetetrazole-induced seizures in mice. Epilepsia 2004;45:1176-1183.
21. Borowicz KK, Swiader M, Drelewska E, Czuczwar SJ: Interactions between riluzole and conventional antiepileptic drugs - a comparison of results obtained in the subthreshold method and isobolographic analysis. J Neural Transm 2004;111:1511-1522.
22. Luszczki JJ, Czuczwar SJ: Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res 2003;56:27-42.
23. Leach JP: Antiepileptic drugs: safety in numbers? Seizure 2000;9:170-178.
24. Rogawski MA, Porter RJ: Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990;42:223-286.
25. Brodie MJ, Schachter SC: Fast Facts. Epilepsy, ed 2. Oxford, Health Press, 2001.